RESUMEN
BACKGROUND: It is well known that suicidal rates vary considerably among European countries and the reasons for this are unknown, although several theories have been proposed. The effect of economic variables has been extensively studied but not that of climate. METHODS: Data from 29 European countries covering the years 2000-2012 and concerning male and female standardized suicidal rates (according to WHO), economic variables (according World Bank) and climate variables were gathered. The statistical analysis included cluster and principal component analysis and categorical regression. RESULTS: The derived models explained 62.4 % of the variability of male suicidal rates. Economic variables alone explained 26.9 % and climate variables 37.6 %. For females, the respective figures were 41.7, 11.5 and 28.1 %. Male suicides correlated with high unemployment rate in the frame of high growth rate and high inflation and low GDP per capita, while female suicides correlated negatively with inflation. Both male and female suicides correlated with low temperature. DISCUSSION: The current study reports that the climatic effect (cold climate) is stronger than the economic one, but both are present. It seems that in Europe suicidality follows the climate/temperature cline which interestingly is not from south to north but from south to north-east. This raises concerns that climate change could lead to an increase in suicide rates. The current study is essentially the first successful attempt to explain the differences across countries in Europe; however, it is an observational analysis based on aggregate data and thus there is a lack of control for confounders.
RESUMEN
BACKGROUND: It is unclear whether there is a direct link between economic crises and changes in suicide rates. AIMS: The Lopez-Ibor Foundation launched an initiative to study the possible impact of the economic crisis on European suicide rates. METHOD: Data was gathered and analysed from 29 European countries and included the number of deaths by suicide in men and women, the unemployment rate, the gross domestic product (GDP) per capita, the annual economic growth rate and inflation. RESULTS: There was a strong correlation between suicide rates and all economic indices except GPD per capita in men but only a correlation with unemployment in women. However, the increase in suicide rates occurred several months before the economic crisis emerged. CONCLUSIONS: Overall, this study confirms a general relationship between the economic environment and suicide rates; however, it does not support there being a clear causal relationship between the current economic crisis and an increase in the suicide rate.
Asunto(s)
Recesión Económica , Suicidio , Adolescente , Adulto , Recesión Económica/estadística & datos numéricos , Recesión Económica/tendencias , Europa (Continente)/epidemiología , Femenino , Producto Interno Bruto/estadística & datos numéricos , Humanos , Internacionalidad , Masculino , Persona de Mediana Edad , Factores de Riesgo , Factores Sexuales , Estadística como Asunto , Suicidio/economía , Suicidio/estadística & datos numéricos , Suicidio/tendencias , Desempleo/estadística & datos numéricosRESUMEN
INTRODUCTION: There are a lot of unresolved issues associated with the classification, diagnosis, clinical management and understanding of the underlying pathogenic mechanisms of bipolar affective disorder. AIM: To search for discrete endophenotypes in BAD. SUBJECTS AND METHODS: We studied various bipolar I and II and recurrent depression patient samples and healthy controls using descriptive data, self and clinician-rated scales for neurological and psychopathological symptoms, neurocognitive instruments, and inventories for temperamental and characterological features. We also looked into the efficacy, tolerability and cost/benefit ratio of sodium valproate in the treatment of acute mania. RESULTS: BAD patients display deficits in the domains of memory, selective attention, working memory and psychomotor speed. Sensory, motor and complex neurological soft signs can be considered part and parcel of the symptomatology of BAD. The evidence linking hyperthymic temperament to the bipolar spectrum is not supported, while cyclothymia seems to be a marker of vulnerability to affective psychopathology. In contrast to others, we found significantly lower self-transcendence in BAD patients compared to controls. Early age of onset, abrupt onset, lability of mood and energy with late-day brightening and activation, discriminate bipolar from unipolar depression. Sodium valproate (especially if started intravenously) is a highly efficacious, cost-effective treatment approach for acute mania. CONCLUSION: The discovery of BAD endophenotypes can enhance early diagnosis, prevent errors in treatment and help elucidate the genetic vulnerability for this grave disease.
Asunto(s)
Trastorno Bipolar/fisiopatología , Endofenotipos , Enfermedad Aguda , Adulto , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/psicología , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/fisiopatología , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Personalidad/efectos de los fármacos , Personalidad/fisiología , Temperamento/efectos de los fármacos , Temperamento/fisiología , Ácido Valproico/administración & dosificación , Ácido Valproico/uso terapéuticoRESUMEN
INTRODUCTION: Whereas the use of electroconvulsive therapy (ECT) has been frequently surveyed in Western Europe, information about the practice of ECT in Eastern Europe is limited. To date, there has been no information about the present state of ECT use in Bulgaria. OBJECTIVE: The aim of this project was to survey current ECT practice in Bulgaria. MATERIALS AND METHODS: A semi-structured questionnaire on the practice of ECT was mailed or e-mailed to all psychiatric inpatient facilities in Bulgaria seeking information about the year 2010. RESULTS: Only 4 inpatient facilities (all university departments) located in Sofia confirmed the use of ECT in 2010. The main indication of ECT was depression, and most of the patients were women. Three of the 4 centers used modern machines for electroencephalographic and electromyographic monitoring. DISCUSSION: This was the first nationwide survey of ECT practice in Bulgaria since 1982. The frequency of ECT use was similarly low as in other Eastern European countries. Approximately 12% of the psychiatric inpatient facilities in Bulgaria offered ECT in 2010, all in the capital city. The lack of availability of ECT outside the capital raises serious concerns about the accessibility of psychiatric care for patients with severe disorders responsive to ECT in other parts of the country.
Asunto(s)
Terapia Electroconvulsiva/estadística & datos numéricos , Anestesia , Anestésicos Intravenosos , Bulgaria , Terapia Electroconvulsiva/métodos , Electroencefalografía , Electromiografía , Encuestas de Atención de la Salud , Hospitales Psiquiátricos/estadística & datos numéricos , Humanos , Trastornos Mentales/terapia , Propofol , Encuestas y CuestionariosRESUMEN
BACKGROUND: Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. METHODS: We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Eligible patients were aged 18-40 years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. 498 patients were randomly assigned by a web-based online system to haloperidol (1-4 mg per day; n=103), amisulpride (200-800 mg per day; n=104), olanzapine (5-20 mg per day; n=105), quetiapine (200-750 mg per day; n=104), or ziprasidone (40-160 mg per day; n=82); follow-up was at 1 year. The primary outcome measure was all-cause treatment discontinuation. Patients and their treating physicians were not blinded to the assigned treatment. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN68736636. FINDINGS: The number of patients who discontinued treatment for any cause within 12 months was 63 (Kaplan-Meier estimate 72%) for haloperidol, 32 (40%) for amisulpride, 30 (33%) for olanzapine, 51 (53%) for quetiapine, and 31 (45%) for ziprasidone. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride (hazard ratio [HR] 0.37, [95% CI 0.24-0.57]), olanzapine (HR 0.28 [0.18-0.43]), quetiapine (HR 0.52 [0.35-0.76]), and ziprasidone (HR 0.51 [0.32-0.81]). However, symptom reductions were virtually the same in all the groups, at around 60%. INTERPRETATION: This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.
Asunto(s)
Antipsicóticos/uso terapéutico , Haloperidol/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Adolescente , Adulto , Amisulprida , Benzodiazepinas/uso terapéutico , Dibenzotiazepinas/uso terapéutico , Femenino , Humanos , Modelos Lineales , Masculino , Olanzapina , Cooperación del Paciente , Piperazinas/uso terapéutico , Modelos de Riesgos Proporcionales , Fumarato de Quetiapina , Sulpirida/análogos & derivados , Sulpirida/uso terapéutico , Tiazoles/uso terapéutico , Resultado del TratamientoRESUMEN
BACKGROUND: Profile and correlates of cognitive deficits in first episode (FE) schizophrenia patients are still debated. The present study is aimed to clarify in a large sample of FE patients the extent of impairment in key cognitive domains and its relationships with demographic and clinical variables. METHOD: The European First Episode Schizophrenia Trial collected demographic, clinical and neurocognitive baseline data in 498 FE patients with minimal or no prior exposure to antipsychotics. Two-hundred-twenty healthy subjects (HS) were also evaluated. Neurocognitive assessment included the Rey Auditory Verbal Learning Test; Trail Making A and B, Purdue Pegboard and Digit-Symbol Coding. RESULTS: Patients performed worse than HS on all tests (effect sizes from -0.88 to -1.73). Correlations with psychopathological dimensions were weak and involved reality distortion and disorganization. The duration of untreated psychosis (DUP) was not associated with cognitive impairment. Subjects living alone had a better neurocognitive performance, while the occupation status did not reveal any association with cognition. CONCLUSIONS: A moderate/severe impairment of processing speed, motor dexterity, verbal memory and cognitive flexibility was found in the largest sample of FE patients analyzed so far. The impairment was largely independent from psychopathology and not associated with DUP.
Asunto(s)
Trastornos del Conocimiento/etiología , Esquizofrenia/complicaciones , Psicología del Esquizofrénico , Estadística como Asunto , Adulto , Antipsicóticos/farmacología , Antipsicóticos/uso terapéutico , Trastornos del Conocimiento/tratamiento farmacológico , Comparación Transcultural , Europa (Continente) , Femenino , Humanos , Cooperación Internacional , Masculino , Análisis Multivariante , Pruebas Neuropsicológicas , Escalas de Valoración Psiquiátrica , Análisis de Regresión , Esquizofrenia/tratamiento farmacológico , Trastornos Relacionados con Sustancias/complicaciones , Trastornos Relacionados con Sustancias/diagnóstico , Adulto JovenRESUMEN
OBJECTIVE: Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. METHODS: Subjects were 498 patients with schizophreniform disorder or first-episode schizophrenia who were randomly assigned to open-label haloperidol (1 to 4 mg/day [N=103]), amisulpride (200 to 800 mg/day [N=104]), olanzapine (5 to 20 mg/day [N=105]), quetiapine (200 to 750 mg/day [N=104]), or ziprasidone (40 to 160 mg/day [N=82]). The Rey Auditory Verbal Learning Test, Trail Making Test Part A and Part B, WAIS Digit Symbol Test, and Purdue Pegboard Test were administered at baseline and the 6-month follow-up evaluation. RESULTS: Compared with scores at baseline, composite cognitive test scores improved for all five treatment groups at the 6-month follow-up evaluation. However, there were no overall differences among the treatment groups. In addition, there was a weak correlation between the degree of cognitive improvement and changes in Positive and Negative Syndrome Scale scores. CONCLUSION: Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. The magnitude of improvement does not differ between treatment with haloperidol and treatment with second-generation antipsychotics. Moreover, cognitive improvement is weakly related to symptom change.
Asunto(s)
Antipsicóticos/efectos adversos , Trastornos del Conocimiento/inducido químicamente , Trastornos Psicóticos/tratamiento farmacológico , Adolescente , Adulto , Antipsicóticos/uso terapéutico , Trastornos del Conocimiento/diagnóstico , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Trastornos Psicóticos/diagnóstico , Esquizofrenia/diagnóstico , Esquizofrenia/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Depression and anxiety frequently coexist in the same individual, either concurrently or at different times, and numerous studies show that the presence of an anxiety disorder is the single strongest risk factor for development of depression. When the two coexist simultaneously, either as diagnosed disorders or subsyndromal states, they may be viewed as mixed anxiety-depression or as comorbid syndromes, i.e. separate disorders occurring concurrently. Controversy continues over the nature of the relationship between depression and anxiety, some believing they are distinct, separate entities while others - now the majority - view them as overlapping syndromes that present at different points on a phenomenological and/or chronological continuum, and share a common neurobiology, the degree of overlap depending on whether each is described at the level of symptoms, syndrome or diagnosis. Community data likely underestimate true prevalence, since affected individuals frequently present in primary care with somatic, rather than psychological, complaints. Irrespective of the nature of the relationship, patients with both disorders experience significant vocational and interpersonal impairment, and more frequent recurrence, with greater likelihood of suicide, than individuals with single disorders. Various classes of antidepressant drugs offer symptom relief for these patients, the most selective of th SSRIs holding the greatest promise for sustained clinical improvement. Yet, the crucial parameter of successful pharmacotherapy seems to be the length of treatment, ensuring enhancement of the compromised neuroprotective and neuroplastic mechanisms. Further clarification of the relationship is a prerequisite for offering effective treatment to the many patients who experience lifetime depression and anxiety.